BenevolentAI
Life science intelligence at your fingertips
- Headquarters
- London
- Employees
- 201–500
- Founded
- 2013
- Business Model
- B2B
- Website
- benevolent.com
- Total Funding
- $115.0M
- Valuation
- $2.0BApr 2018
- Last Round
- $115.0M Venture RoundApr 2018
About
BenevolentAI is a clinical-stage, AI-enabled drug discovery and development company listed on Euronext Amsterdam. Founded in 2013, the company uses its proprietary Benevolent Platform — built on a decade of investment in knowledge graphs and ontologies — to integrate life science data and augment scientific decision-making. Headquartered in London with offices in Cambridge and New York, BenevolentAI partners with pharmaceutical companies and pursues its own pipeline for complex diseases.